Joshua Berg, MD
Infectious Disease · Carmel, INNPI 1851504518
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 36.2% of the total. Reporting peaked in 2021 at $493 and has fallen 78.4% since, to $106 in 2025.
Across 52 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$532
- Viiv Healthcare Company$359
- Cipla USA Inc.$317
- La Jolla Pharmaceutical Company$127
- Insmed, Inc.$43
- Tetraphase Pharmaceuticals, Inc.$26
- plus $67 from 4 others
What the payments were for
- Food & beverage$1,471100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $532 |
| Viiv Healthcare Company | 20 | $359 |
| Cipla USA Inc. | 1 | $317 |
| La Jolla Pharmaceutical Company | 1 | $127 |
| Insmed, Inc. | 2 | $43 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $26 |
| Gilead | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Angiodynamics, Inc. | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEMDRI (PLAZOMICIN)$317
- XACDURO$127
- DALVANCE$122
How this compares
$1,471 in reported general payments places this provider in the 75th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 44 | $21,684 |
| Cefepime Hcl | 44 | $14,546 |
| CeftriaxoneCeftriaxone Sodium | 57 | $9,594 |
| Meropenem | 16 | $7,586 |
| ErtapenemErtapenem Sodium | 12 | $6,843 |
| Vancomycin Hcl | 28 | $2,504 |
| Cefazolin Sodium | 18 | $1,827 |
| Rifampin | 13 | $697 |
| Cephalexin | 14 | $290 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Carmel
- Markian BochanCarmel$54K
- Tracey IkerdCarmel$39K
- Francisco DelgadoCarmel$3K
- Chad TewellCarmel$1K
- Hassan ElmalikCarmel$1K
- Joseph FraizCarmel$676
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.